Abstract
In countries with mature generalized epidemics such as Uganda, there are still groups of individuals that are disproportionately affected by HIV. These most at risk populations (MARPs) have high HIV prevalence compared to the general population. Among the MARPs in Uganda are fishing communities, which make up about 10% of the population. We investigated the impact of combined HIV prevention interventions on HIV transmission dynamics in high-risk fishing communities in Uganda using a deterministic compartmental model. The projected HIV incidence decreased from 1.87 per 100 PY without intervention scale-up to 0.25 per 100 PY after 15 years of intervention scale-up. A potential combination achieving this 87% reduction in incidence included condom use in about 60% of sexual acts, 23% of susceptible men circumcised, 87% of people living with HIV aware of their status, 75% of those on ART, and about 3% of susceptible individuals on oral PrEP. Sensitivity analyses revealed that condom use and early ART were the most important intervention components. Reducing HIV incidence, and consequently prevalence and AIDS-related mortality, in these high-risk fishing communities in Uganda is attainable in the long-run with a combination prevention package. Our projected levels are well within the national targets set by the Uganda government and close to reaching the UNAIDS 95-95-95 goal to end AIDS by 2030.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Project carried out with the support of the Fund AIDS managed by the King Baudouin Foundation. RNN was funded to visit Hasselt by Hasselt University Special Research Fund (BOF) Programme for incoming mobility. The HIVCOMB Study was jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement. Award Number MR/L004305/1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The HIVCOMB study was approved by the Uganda Virus Research Institute, the Uganda National Council of Science and Technology, and the London School of Hygiene and Tropical Medicine ethics committees.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
R code accompanying this manuscript is available on GitHub.